A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)

NCT00628342 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease (GERD)

Interventions

DRUG: Esomeprazole
DRUG: Esomeprazole
DRUG: Placebo

Sponsor

AstraZeneca